Trial | Year | Treatment | N | Age (mean±SD), median (IQR) | Age >75 | Males | Hypertension | Diabetes | Heart failure | Stroke | CHADS2≥2 | Control |
---|---|---|---|---|---|---|---|---|---|---|---|---|
LAAC trials | ||||||||||||
PREVAIL | 2014 | Watchman | 269 | 74.0±7.4 | 140 | 182 | 238 | 91 | 63 | 74 | 248 | Warfarin |
PROTECT-AF | 2013 | Watchman | 463 | 71.7±8.8 | 190 | 326 | 415 | 113 | 124 | 82 | 307 | Warfarin |
NOAC trials | ||||||||||||
ENGAGE-AF | 2013 | Edoxaban | 14 069 | 72 (64–78) | 5654 | 8670 | 13 166 | 5103 | 8076 | 3982 | NA | Warfarin |
J-ROCKET-AF | 2012 | Rivaroxaban | 639 | 71 (34–89) | 252 | 530 | 508 | 249 | 264 | NA | 639 | Warfarin |
ROCKET-AF | 2011 | Rivaroxaban | 7131 | 73 (65–78) | NA | 4300 | 6436 | 2878 | 4467 | 3916 | 7130 | Warfarin |
ARISTOTLE | 2011 | Apixaban | 9120 | 70 (63–76) | 2850 | 5986 | 7962 | 2284 | 3235 | 1748 | 6020 | Warfarin |
RELY | 2009 | Dabigatran | 12 091 | 71.5±8.8 | NA | 7705 | 9533 | 2811 | 3871 | 2428 | 8174 | Warfarin |
PETRO | 2007 | Dabigatran | 432 | 70.0±8.3 | 139 | 352 | 307 | 111 | 123 | 74 | NA | Warfarin |
WARFARIN trials | ||||||||||||
PREVAIL | 2014 | Warfarin | 138 | 74.9±7.2 | 78 | 103 | 134 | 41 | 32 | 39 | 126 | LAAC |
PROTECT-AF | 2013 | Warfarin | 244 | 72.7±9.2 | 115 | 171 | 220 | 72 | 66 | 49 | 178 | LAAC |
ENGAGE-AF | 2013 | Warfarin | 7036 | 72 (64–78) | 2820 | 4575 | 6588 | 2521 | 4048 | 1991 | NA | Edoxaban |
J-ROCKET-AF | 2012 | Warfarin | 639 | 71.2 (43–90) | 246 | 500 | 508 | 237 | 257 | NA | 639 | Rivaroxaban |
ROCKET-AF | 2011 | Warfarin | 7133 | 73 (65–78) | NA | 4301 | 6474 | 2817 | 4441 | 3895 | 7131 | Rivaroxaban |
ARISTOTLE | 2011 | Warfarin | 9081 | 70 (63–76) | 2828 | 5899 | 7954 | 2263 | 3216 | 1790 | 5998 | Apixaban |
RELY | 2009 | Warfarin | 6022 | 71.6±8.6 | NA | 3809 | 4750 | 1410 | 1922 | 1195 | 4163 | Dabigatran |
PETRO | 2007 | Warfarin | 70 | 69.0±8.3 | 19 | 59 | 49 | 15 | 24 | 13 | NA | Dabigatran |
BAFTA | 2007 | Warfarin | 488 | 81.5±4.3 | 488 | 267 | 259 | 68 | 96 | 64 | 139 | Aspirin |
WASPO | 2007 | Warfarin | 36 | 83.5 (80–90) | NA | 14 | 17 | 1 | 9 | NA | NA | Aspirin |
Vemmos et al24 | 2006 | Warfarin | 16 | 80.1±2.5 | NA | 7 | 10 | 2 | 1 | NA | NA | Aspirin |
ACTIVE-W | 2006 | Warfarin | 3371 | 70.2±9.5 | NA | 2211 | 2767 | 717 | 1040 | 510 | NA | DAPT |
WARSS | 2001 | Warfarin | 1103 | 63.3±11.2 | NA | 656 | 746 | 367 | NA | 321 | NA | Aspirin |
PATAF | 1999 | Warfarin | 131 | 75.2 | NA | 58 | 46 | 25 | NA | NA | NA | Aspirin |
AFASAK II | 1999 | Warfarin | 170 | 74.2±7.7 | NA | 97 | 80 | NA | NA | 9 | NA | Aspirin |
SPAF II | 1994 | Warfarin | 197 | 64±8 80±3 | NA | NA | NA | NA | NA | NA | NA | Aspirin |
EAFT | 1993 | Warfarin | 225 | 71.0±7.0 | NA | 124 | 97 | 27 | 18 | NA | NA | Placebo/aspirin |
SPAF | 1991 | Warfarin | 210 | 67 | 17 | 155 | 103 | 25 | 29 | 17 | NA | Placebo |
AFASAK | 1989 | Warfarin | 335 | 72.8 (41–88) | NA | 176 | 108 | 25 | 168 | 16 | NA | Placebo/aspirin |
ANTIPLATELET trials | ||||||||||||
BAFTA | 2007 | Aspirin | 485 | 81.5±4.2 | 485 | 264 | 269 | 61 | 94 | 60 | 136 | Warfarin |
WASPO | 2007 | Aspirin | 39 | 82.6 (80–90) | NA | 21 | 18 | 2 | 10 | NA | NA | Warfarin |
Vemmos et al24 | 2006 | Aspirin | 15 | 79.5±2.9 | NA | 9 | 11 | 1 | 2 | NA | NA | Warfarin |
ACTIVE W | 2006 | DAPT | 3335 | 70.2±9.4 | NA | 2219 | 2755 | 712 | 991 | 510 | NA | Warfarin |
WARSS | 2001 | Aspirin | 1103 | 62.6±11.4 | NA | 653 | 753 | 338 | NA | 308 | NA | Warfarin |
PATAF | 1999 | Aspirin | 141 | 75.2 | NA | 67 | 53 | 21 | NA | NA | NA | Warfarin |
AFASAK II | 1999 | Aspirin | 169 | 73.1±7.2 | NA | 110 | 73 | NA | NA | 9 | NA | Warfarin |
SPAF II | 1994 | Aspirin | 188 | 64±8 80±3 | NA | NA | NA | NA | NA | NA | NA | Warfarin |
EAFT | 1993 | Aspirin | 404 | 73.0±8.0 | NA | 238 | 198 | 53 | 44 | NA | NA | Warfarin |
AFASAK | 1989 | Aspirin | 336 | 75.1 (40–91) | NA | 184 | 112 | 26 | 183 | 12 | NA | Warfarin |
PLACEBO trials | ||||||||||||
EAFT | 1993 | Placebo | 378 | 73.0±8.0 | NA | 200 | 178 | 49 | 45 | NA | NA | Warfarin |
SPAF | 1991 | Placebo | 211 | 67.0 | 17 | 148 | 116 | 40 | 40 | 17 | NA | Warfarin |
AFASAK | 1989 | Placebo | 336 | 74.6 (38–91) | NA | 180 | 103 | 33 | 170 | 15 | NA | Warfarin |
DAPT, dual antiplatelet therapy; IQR, interquartile range; LAAC, left atrial appendage closure; NA, not available; SD, standard deviation.